Gene Therapy for CNS Disorders Market Report – Research, Industry Analysis Reports and Market Demands

Global Gene Therapy for CNS Disorders Market Growth (Status and Outlook) 2019-2024

Request for Sample of this report

Buy now

Table of Content

2019-2024 Global Gene Therapy for CNS Disorders Market Report (Status and Outlook)

1 Scope of the Report

2 Executive Summary

2.1 World Market Overview
- 2.1.1 Global Gene Therapy for CNS Disorders Market Size 2014-2024
- 2.1.2 Gene Therapy for CNS Disorders Market Size CAGR by Region
2.2 Gene Therapy for CNS Disorders Segment by Type
- 2.2.1 Ex Vivo
- 2.2.2 In Vivo
2.3 Gene Therapy for CNS Disorders Market Size by Type
- 2.3.1 Global Gene Therapy for CNS Disorders Market Size Market Share by Type (2014-2019)
- 2.3.2 Global Gene Therapy for CNS Disorders Market Size Growth Rate by Type (2014-2019)
2.4 Gene Therapy for CNS Disorders Segment by Application
- 2.4.1 Hospitals
- 2.4.2 Clinics
- 2.4.3 Others
2.5 Gene Therapy for CNS Disorders Market Size by Application
- 2.5.1 Global Gene Therapy for CNS Disorders Market Size Market Share by Application (2014-2019)
- 2.5.2 Global Gene Therapy for CNS Disorders Market Size Growth Rate by Application (2014-2019)

3 Global Gene Therapy for CNS Disorders by Players

3.1 Global Gene Therapy for CNS Disorders Market Size Market Share by Players
- 3.1.1 Global Gene Therapy for CNS Disorders Market Size by Players (2017-2019)
- 3.1.2 Global Gene Therapy for CNS Disorders Market Size Market Share by Players (2017-2019)
3.2 Global Gene Therapy for CNS Disorders Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
- 3.3.1 Competition Landscape Analysis
- 3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 Gene Therapy for CNS Disorders by Regions

4.1 Gene Therapy for CNS Disorders Market Size by Regions
4.2 Americas Gene Therapy for CNS Disorders Market Size Growth
4.3 APAC Gene Therapy for CNS Disorders Market Size Growth
4.4 Europe Gene Therapy for CNS Disorders Market Size Growth
4.5 Middle East & Africa Gene Therapy for CNS Disorders Market Size Growth

5 Americas

5.1 Americas Gene Therapy for CNS Disorders Market Size by Countries
5.2 Americas Gene Therapy for CNS Disorders Market Size by Type
5.3 Americas Gene Therapy for CNS Disorders Market Size by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC

6.1 APAC Gene Therapy for CNS Disorders Market Size by Countries
6.2 APAC Gene Therapy for CNS Disorders Market Size by Type
6.3 APAC Gene Therapy for CNS Disorders Market Size by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries

7 Europe

7.1 Europe Gene Therapy for CNS Disorders by Countries
7.2 Europe Gene Therapy for CNS Disorders Market Size by Type
7.3 Europe Gene Therapy for CNS Disorders Market Size by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa

8.1 Middle East & Africa Gene Therapy for CNS Disorders by Countries
8.2 Middle East & Africa Gene Therapy for CNS Disorders Market Size by Type
8.3 Middle East & Africa Gene Therapy for CNS Disorders Market Size by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers and Impact
- 9.1.1 Growing Demand from Key Regions
- 9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Global Gene Therapy for CNS Disorders Market Forecast

10.1 Global Gene Therapy for CNS Disorders Market Size Forecast (2019-2024)
10.2 Global Gene Therapy for CNS Disorders Forecast by Regions
- 10.2.1 Global Gene Therapy for CNS Disorders Forecast by Regions (2019-2024)
- 10.2.2 Americas Market Forecast
- 10.2.3 APAC Market Forecast
- 10.2.4 Europe Market Forecast
- 10.2.5 Middle East & Africa Market Forecast
10.3 Americas Forecast by Countries
- 10.3.1 United States Market Forecast
- 10.3.2 Canada Market Forecast
- 10.3.3 Mexico Market Forecast
- 10.3.4 Brazil Market Forecast
10.4 APAC Forecast by Countries
- 10.4.1 China Market Forecast
- 10.4.2 Japan Market Forecast
- 10.4.3 Korea Market Forecast
- 10.4.4 Southeast Asia Market Forecast
- 10.4.5 India Market Forecast
- 10.4.6 Australia Market Forecast
10.5 Europe Forecast by Countries
- 10.5.1 Germany Market Forecast
- 10.5.2 France Market Forecast
- 10.5.3 UK Market Forecast
- 10.5.4 Italy Market Forecast
- 10.5.5 Russia Market Forecast
- 10.5.6 Spain Market Forecast
10.6 Middle East & Africa Forecast by Countries
- 10.6.1 Egypt Market Forecast
- 10.6.2 South Africa Market Forecast
- 10.6.3 Israel Market Forecast
- 10.6.4 Turkey Market Forecast
- 10.6.5 GCC Countries Market Forecast
10.7 Global Gene Therapy for CNS Disorders Forecast by Type
10.8 Global Gene Therapy for CNS Disorders Forecast by Application

11 Key Players Analysis

11.1 Gilead (Kite Pharma)
- 11.1.1 Company Details
- 11.1.2 Gene Therapy for CNS Disorders Product Offered
- 11.1.3 Gilead (Kite Pharma) Gene Therapy for CNS Disorders Revenue, Gross Margin and Market Share (2017-2019)
- 11.1.4 Main Business Overview
- 11.1.5 Gilead (Kite Pharma) News
11.2 Amgen (BioVex)
- 11.2.1 Company Details
- 11.2.2 Gene Therapy for CNS Disorders Product Offered
- 11.2.3 Amgen (BioVex) Gene Therapy for CNS Disorders Revenue, Gross Margin and Market Share (2017-2019)
- 11.2.4 Main Business Overview
- 11.2.5 Amgen (BioVex) News
11.3 Novartis
- 11.3.1 Company Details
- 11.3.2 Gene Therapy for CNS Disorders Product Offered
- 11.3.3 Novartis Gene Therapy for CNS Disorders Revenue, Gross Margin and Market Share (2017-2019)
- 11.3.4 Main Business Overview
- 11.3.5 Novartis News
11.4 Roche (Spark Therapeutics)
- 11.4.1 Company Details
- 11.4.2 Gene Therapy for CNS Disorders Product Offered
- 11.4.3 Roche (Spark Therapeutics) Gene Therapy for CNS Disorders Revenue, Gross Margin and Market Share (2017-2019)
- 11.4.4 Main Business Overview
- 11.4.5 Roche (Spark Therapeutics) News
11.5 Bluebird Bio
- 11.5.1 Company Details
- 11.5.2 Gene Therapy for CNS Disorders Product Offered
- 11.5.3 Bluebird Bio Gene Therapy for CNS Disorders Revenue, Gross Margin and Market Share (2017-2019)
- 11.5.4 Main Business Overview
- 11.5.5 Bluebird Bio News

...

12 Research Findings and Conclusion

Description

Gene Therapy is an experimental treatment that involves introducing genetic material into a person’s cells to fight or prevent disease. A gene can be delivered to a cell using a carrier known as a “vector.” The most common types of vectors used in gene therapy are viruses. The viruses used in gene therapy are altered to make them safe, although some risks still exist with gene therapy. The technology is still in its infancy.

According to this study, over the next five years the Gene Therapy for CNS Disorders market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Gene Therapy for CNS Disorders business, shared in Chapter 3.

This report presents a comprehensive overview, market shares and growth opportunities of Gene Therapy for CNS Disorders market by product type, application, key companies and key regions.

This study considers the Gene Therapy for CNS Disorders value generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019 in Section 2.3; and forecast to 2024 in section 10.7.
Ex Vivo
In Vivo
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 10.8.
Hospitals
Clinics
Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Gilead (Kite Pharma)
Amgen (BioVex)
Novartis
Roche (Spark Therapeutics)
Bluebird Bio
...

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Gene Therapy for CNS Disorders market size by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Gene Therapy for CNS Disorders market by identifying its various subsegments.
Focuses on the key global Gene Therapy for CNS Disorders players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Gene Therapy for CNS Disorders with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the size of Gene Therapy for CNS Disorders submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.